10/009566 Rec'd PCT/PTO 12 DEC 2001

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT No.	APPLICATION NO.
033025-002	Unessigned 10 /009, 500
APPLICANT	
Nachiro TAKEMOTO tal	
FILING DATE	GROUP 1/22C
Documber 12, 2001	Hospital 1625

	THE PILE	30.4	WESTKEMUDOO WETKAN 28.0	对	
	U.S. Patent D	ocument			
Examiner		Kind Code	Name of Patentee or Applican		
Initials	Number	(if known)	of Cited Document	(MM-DD-Y)	(44)
				•	
•					
					_
		\$\[\frac{1}{2}\] \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \	BITEUN EXPLEXAL DOCUMENTOS		
	Foreign Patent	Document			
Examiner Initlals	Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation
	WO 00 23076	A	WiPO	04-27-00	Yes no
Vale	0 982 026 A	A	EPO	03-01-00	<del>  -   -  </del>
1	0 002 020 A		210	00 01 00	
					<del>                                     </del>
					<b>-</b>
					+
					-
	New Action Control of the Control of				GIGN NO ASPIEL
			रणचश्रुपुरोषण्वःभ्रुगुणग्रंबं छ <b>ं</b> ठलण्यां		
Examiner Initials	include item (book,	name of author magazine, jourr	(in CAPITAL LETTERS), title of the arti nal, serial, symposium, catalog, etc.), d publisher, city and/or country where p	late, page(s), volume-issue num	the ber(s),
210	Bouillon et al., "Anta 1995, pp.484-90, v	agonistic activit ol. 60,Elsevier S	y of 24-oxa-analogs of vitamin D," <i>Ste</i> Science Publishers, New York, New Yo	riods: Structure, Function, and rk, USA.	Regulation,
<i>O</i>					
		-			
				<del> </del>	
	<del></del>			<del> </del>	
			<del></del>		
Examiner Signature	gat a	2 Cpm	Date Considered	2/13/04	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, O.C. 20231.

		SUEE! T OF T
, Substitute for form 1449A/PTO	ATTORNEY'S DKT NO. 033025-002	APPLICATION NO. 10/009,566
INFORMATION DISCLOSURE	APPLICANT Nachiro TAKEMOTO et a	al.
. STATEMENT BY APPLICANT	FILING DATE December 12, 2001	GROUP Unassigned 1625

	Y S S	:	S: PATIENT DOCUMENTS		
The state of the s	U.S. Patent	Document			
Examiner	ACEMA	Kind Code	Name of Patentee or Appli	icant Date of Put	dication
Initials	Number	(if known)	of Cited Document	(MM-DD-	
					<u> </u>
				8 7	ň
		<u> </u>		3 5	Ò
				空。	M
				E 3	2
					M
				8. 7	0
				18	
		<del>                                     </del>		3	·
	\$1750XX	The state of the s	EIGN PATIENTEDOCUMEN		
	Foreign Paten				
Examiner Initials	Number .	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Yes no
	110111001	THE RESERVE OF THE PERSON OF T	- Country	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Yes no
	<del>                                     </del>	1 - 1	<del></del>		
	<del></del>	+			
74 7		A NON PAY	MOOO EKANAYENIN JUVEN	MENUS (	
Examiner Initials	Include item (bool	k, magazine, journal,	CAPITAL LETTERS), title of the , serial, symposium, catalog, etc ublisher, city and/or country who	article (when appropriate), title o c.), date, page(s), volume-issue nu ere nublished	f the mber(s),
0.4.1	McMahon et al			cium and promotes resistance	e to
ghe			olecular Brain Research, 1		
gre	Ng et al., "The neurons". Mole	neurotoxin MP	TP increases calbindin-D <sub>28k</sub> earch, 1996, 36:329-336.	k levels in mouse midbrain d	opaminergi
				n fact or receptor-1 mRNA a	fter transies
ga				ce Letters, 1996, 213:119-12	
					<del></del>
			· · · · · · · · · · · · · · · · · · ·		
			<u> </u>	·	
	l				
			•		
×aminer		L apri	Date	ed 2/13/04	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.